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Objectives: To evaluate Fourier transform infrared (FTIR) spectroscopy as a rapid method for dis-
tinguishing glycopeptide-intermediate Staphylococcus aureus (GISA) from glycopeptide-susceptible
methicillin-resistant S. aureus (MRSA) and to compare three data analysis methods.
Methods: First-derivative normalized spectra of dried films of bacterial growth on Que-Bactw Universal
Medium No. 2 were examined by singular value decomposition to identify key spectral regions. Region
selection was analysed by principal component analysis (PCA), self-organizing maps (SOMs) and the
K-nearest neighbour (KNN) algorithm. The initial data set included 35 GISA (including GISA Mu50 and
heterogeneous GISA Mu3) and 25 epidemic MRSA. The regions were then tested using enlarged data
sets that included 22 sporadic and 85 additional epidemic MRSA.
Results: Epidemic MRSA and GISA/hGISA were separated into two distinct clusters on the basis of
spectral data from regions 1352–1315 and 1480–1460 cm21, the former providing 100% correct classifi-
cation by all three analyses and the latter providing 96.67% correct by PCA, 98.34% by SOM and 100%
by KNN. The 1480–1460 cm21 region was more effective for distinguishing GISA/hGISA from a set
combining sporadic and epidemic MRSA, with two GISA/hGISA and four sporadic MRSA misclassified
by PCA and SOM (92.69% correct), while the KNN method misclassified three of the four sporadic
MRSA (93.90% correct). The addition of 85 other epidemic MRSA this set increased the fraction of cor-
rectly classified isolates to 96.41% and 97.01% by PCA, SOM and KNN, respectively.
Conclusions: As only 6 of 167 isolates were misclassified, FTIR spectroscopy may provide means of
rapid and accurate identification of GISA and hGISA among isolates of MRSA.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is one of
the most common agents of community-acquired and nosoco-
mial infections worldwide, causing high morbidity and mor-
tality. For the past three decades, glycopeptides have been the
antibiotics of choice for the treatment of MRSA infections. In
recent years, however, MRSA with varying degrees of reduced
susceptibility to glycopeptides have emerged, the so-called
‘glycopeptide-intermediate’ strains or GISA. These are charac-
terized by MICs of 8–16 mg/L for teicoplanin and 8 mg/L for
vancomycin. This situation is complicated by heterogeneous
forms called hGISA, with MICs of 16 mg/L for teicoplanin and
1–4 mg/L for vancomycin. These appear to give rise to sub-
populations able to grow in the presence of over 4 mg/L of van-
comycin at a frequency of 1026 or higher1 – 4 and may underlie
some failures of vancomycin therapy.5 – 7 However, the true
clinical incidence and significance of hGISA remain unclear.
The mechanism of glycopeptide resistance has not been fully
defined and clinical detection continues to rely on growth and
susceptibility in selective media, often giving ambiguous
results.1,5,8,9 Thus there is a need in clinics for a more reliable
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method of screening MRSA for the glycopeptide resistance trait.
Such a method should be simple and rapid and offer high repro-
ducibility both within and between laboratories.
The GISA/hGISA phenotype may be confirmed by popu-
lation analysis1 and/or by electron microscopy (thickened cell
wall), both too complex and costly for routine clinical practice.
The gold standard method, used in a number of surveillance
studies for GISA and hGISA, is the population analysis profile
(PAP)-area under the curve (AUC),10 – 12 with criteria specifi-
cally designed to discriminate between glycopeptide-susceptible
S. aureus, hGISA and GISA. Ideally, PAP-AUC would be used
in clinics to confirm the GISA/hGISA phenotypes when ident-
ified by a reliable and preferably rapid screening method.
Several screening methods and agars for GISA/hGISA have
been reported.1,13,14 In a recent international study involving 12
laboratories,15 the macro-method Etest (MET) and Mueller–
Hinton agar (MHA) with 5 mg/L teicoplanin provided correct
identification of 82.5% and 85.9% of 48 test strains, whereas
brain–heart infusion agar (BHIA) broth with 6 mg/L vancomycin
identified only 11.5% of the hGISA in the set and gave the
highest inter-laboratory variability for GISA in general.
The GISA phenotype is associated with alterations in the
cell-wall peptidoglycan synthesis pathway and increased levels
of penicillin-binding proteins (PBP2), resulting in thickened cell
walls.16 Biochemical characteristics such as these are detectable
by Fourier transform infrared (FTIR) spectroscopy, a non-
destructive technique that can be used to probe the total
composition of intact microbial cells without the use of reagents.
Complex yet distinct and reproducible spectral signatures
or ‘fingerprints’ of microorganisms may be obtained for
identification purposes, even down to the subspecies17 – 22 and
antibiotic resistance phenotypes.23 – 25 On the basis of these find-
ings, the present study was undertaken to evaluate its potential
as a superior alternative to conventional clinical screening
methods for distinguishing the GISA/hGISA phenotype from
glycopeptide-susceptible S. aureus.
Materials and methods
Clinical specimens and microbiological analysis
The 35 GISA/hGISA isolates were obtained from the Network on
Antimicrobial Resistance in S. aureus (NARSA) collection. These
included 31 methicillin-resistant and 4 methicillin-susceptible
GISA/hGISA isolates. Heterogeneous GISA strain Mu3 and GISA
strain Mu50 were included among the 31 methicillin-resistant
GISA/hGISA. Eighty-five isolates of epidemic MRSA and 22 iso-
lates of sporadic MRSA were provided by the Health Canada
National Microbiology Laboratory (NML). Another 25 epidemic
MRSA were provided by the Royal Victoria Hospital (Montreal,
QC, Canada).
Testing for glycopeptide-intermediate resistance in all GISA/
hGISA was performed by NARSA using broth microdilution (BMD)
with frozen and dried panels; conventional MET with MHA, 0.5
McFarland inoculum and 24 h incubation at 358C (MHA-CMET);
the modified MET with BHIA, 2.0 McFarland inoculum and 48 h
incubation at 358C (BHIA-MMET); the BHIA screen assay (24, 48
and 72 h growth of 10 mL spot on agar containing 6 mg/L vancomy-
cin or BHIA-6V); and the conventional disc diffusion method (DD).
In fact, identification of an isolate as GISA or hGISA by NARSA is
based solely on the BHIA-MMET method.
FTIR spectroscopic methods
Sample preparation. All isolates were grown from frozen stocks
kept at 2708C in BHI broth containing 15% glycerol, by overnight
subculture on tryptic soy agar with sheep blood (Quelab Laboratories
Inc., Montreal, QC, Canada) at 378C. A single colony was collected,
streaked in a four-quadrant pattern onto four plates of Que-Bactw
Universal Medium No. 2 agar (Quelab Laboratories Inc.), which
were then incubated for 18 h at 378C. Cells were then carefully col-
lected from a single quadrant of each plate using a 10 mm diameter
soft plastic loop (10 mL, COP-S10, Copan Diagnostics Inc., Corona,
CA, USA). All surfaces of the loop head are ultra-smooth for easy
streaking or harvesting of growth, without damaging or scraping the
agar surface. Collected colonies were suspended in the same 200 mL
aliquot of sterile physiological saline (0.9% NaCl), which was then
diluted 10-fold in saline to a cell concentration of 5  1011 cfu/
mL. A 25 mL droplet of diluted suspension was deposited on a clean
zinc selenide (ZnSe) optical window (13 mm diameter, 2 mm thick,
two windows per aluminium slide) and oven-dried at 488C for 1 h to
form a thin and transparent homogeneous dried film for FTIR
measurement. Four films were made for each isolate.
Spectral acquisition. All FTIR spectra were acquired in the trans-
mission mode using a Bomem MB-104 (ABB-Bomem, Quebec,
QC, Canada) FTIR spectrometer equipped with a non-hygroscopic
ZnSe beamsplitter and a deuterated triglycine sulphate detector and
operating under Bomem-Grams/386 software (Galactic, Salem, NH,
USA). The spectrometer was purged with dry CO2-free air from a
Balston dryer (Balston, Lexington, MA, USA) to minimize interfer-
ence from atmospheric water vapour and CO2. To enhance the
signal-to-noise ratio, 64 scans were co-added at 4 cm21 resolution
over the wavenumber range of 4000–400 cm21 and ratioed against
an open-beam background to obtain an absorbance spectrum. A
single spectrum was thus obtained for each of the four windows
made for each strain.
Tentative assignments of spectral features based on the compari-
son of resolution-enhanced microbial IR spectra with IR spectra of
known building blocks inherent in intact cells are described as
follows.26
The spectral region of 3000–2800 cm21 is dominated by broad
features resulting from vibrations of –CH3, .CH2 and CH func-
tional groups of fatty acid aliphatic chains. The region between
1800 and 1500 cm21 contains bands corresponding to protein and
peptide components such as amides I and II. The 1500–1200 cm21
region is mixed and contains vibrations corresponding to carboxylic
groups of proteins, free amino acids and polysaccharides as well as
vibrations of phosphate, RNA/DNA and phospholipids. The 1200–
900 cm21 region is dominated by absorption bands corresponding to
cell-wall carbohydrates. The 900–700 cm21 region is yet to be
associated with specific components.
Mathematical pre-processing and processing. Spectra acquired in
Grams SPC format were converted into comma-separated value files
and then into MATLAB files using MATLAB version 5.1 (The
MathWorks, Inc., Natick, MA, USA). Because band intensity varies
as a function of film thickness, the spectral data over the whole
spectral range (4000–400 cm21) were normalized to unit height by
vector transformation to compensate for differences in film thickness
and then transformed to the first derivative using the Savitzky–
Golay algorithm to maximize peak separation, enhance apparent
resolution and minimize problems arising from baseline shifts.
Prior to data processing, spectral feature selection was performed
by singular value decomposition (SVD)27 using pairs of spectra and
confirmed by visual examination of the normalized spectra. Data
were processed using two exploratory data analysis methods, namely,
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principal component analysis or PCA (employing the non-linear
iterative partial-least-squares algorithm28) and the self-organizing
map (SOM) algorithm.29 Cluster analysis was performed using the
K-nearest neighbours (KNN) algorithm.30 Programs were written in
MATLAB version 5.1 to implement the data pre-processing and
processing algorithms.
SVD algorithm. Spectral regions having features with the poten-
tial to distinguish all the strains were pre-selected using the SVD
algorithm.27 The SVD algorithm inspects IR spectral region vectors
(columns of matrix U and absorbance at specific wavenumbers)
corresponding to the most significant features and compares each
vector to a threshold value. If the threshold is exceeded, the corre-
sponding spectral region is assigned to the clustering set.
Principal component analysis. PCA is a multivariate procedure
that rotates data to maximize the variability projected onto axes. A
set of correlated variables is thus transformed to a set of uncorre-
lated variables ranked by variability in the descending order.28 The
resulting uncorrelated variables are linear combinations of the orig-
inal variables and the last of these can be removed with minimal
loss of real data. PCA is used mainly to reduce the dimensionality
of a data set while retaining as much information as possible by
computing a compact and optimal description of the data set. The
first principal component (PC1) is the combination of variables that
accounts for the greatest amount of the total variation. The second
principal component (PC2) defines the largest amount of the
remaining variation and is orthogonal to the first principal com-
ponent. The number of principal components possible is equal to
the number of variables. In addition to reducing the number of
variables and detecting structural relationship between variables, a
PCA plot shows spectral data distribution and hence the existence
of clusters.
Self-organizing maps. SOM is a data visualization technique that
uses unsupervised self-organizing neural networks to reduce the
dimensionality of data to a level that humans can comprehend.29
This usually means producing a one- or two-dimensional map that
plots similarities by grouping similar data items together. The map
consists of a regular grid of processing units or ‘neurons’. Each
neuron k is represented by an n-dimensional prototype vector
mk ¼ [mk1,. . .., mkn] where n is the dimension of the input space. At
each training step, a data sample x is selected and the nearest neuron
mc [referred to as the best matching unit (BMU)] is found. The pro-
totype vectors of the BMU and its neighbours on the grid are moved
towards the sample vector according to the relation:
mk:¼ mk þ aðtÞhckðtÞðx mkÞ
where a(t) is the learning rate and hck(t) is a neighbourhood kernel
centred on the BMU. Both learning rate and neighbourhood kernel
radius decease monotonically with time. During iterative training of
the network, a multidimensional model emerges, containing all the
spectral features associated with each prototype vector. The map
attempts to represent all the available observations with optimal
accuracy using a restricted set of models (neurons) of meaningful
two-dimensional order. At the same time, models or neurons
become ordered on the grid according to their similarity to each
other, resulting in a clustering diagram.29
K-nearest neighbour. The KNN classifier is a non-parametric
similarity classification-based method that attempts to categorize
unknown samples based on multivariate proximity to other samples
of pre-assigned categories. The distance matrix is sorted and the dis-
tance of the unknown sample is compared with its KNNs. The iden-
tity of an unknown sample is based on the class of the nearest
known samples, that is, by assigning the class shared by the
majority of nearest neighbours to the unknown. Each class rep-
resents a bacterial strain type in the data set. The optimal number K
of neighbours used to predict an unknown was determined from the
highest number of correctly classified points obtained with K set at
1 through 10.30
Results and discussion
The emergence of S. aureus in many parts of the world with
decreased susceptibility to glycopeptide antimicrobial agents
such as vancomycin and teicoplanin is a major concern.9 It is
particularly worrisome that hetero-resistant strains (hGISA)
appear susceptible based on the conventional testing, but give
rise to more resistant forms at a frequency of about one cell per
million. Both GISA and hGISA confound routine methods used
in diagnostic laboratories. The use of BHI agar with 6 mg/L
vancomycin (BHIA-6V) or of Mueller–Hinton agar with
5 mg/L teicoplanin and the MET appears to be ,86% accurate
and with considerable inter-laboratory variability.15 The true
clinical incidence of GISA and in particular hGISA will not be
known until a reliable detection method is available at a cost
affordable by diagnostic laboratories. Such a method must mini-
mize false-positive results, as it would be highly desirable to do
the expensive confirmatory tests (PAP-AUC) when screening
results are positive. Diagnostic laboratories will therefore assess
the performance of any GISA/hGISA screening method in terms
of cost-effectiveness. Reproducibility and variability of perform-
ance between laboratories is of concern, especially for public
health and research. FTIR spectroscopy has the potential to offer
a method that is affordable and reproducible both within and
between laboratories.
Spectral reproducibility
The fundamental requirement for IR analysis of microorganisms
is that the variance among spectra of a single taxon be less than
that among spectra of different taxa.31 In this context, it should
be emphasized that IR spectroscopy is sensitive to phenotypic
rather than genotypic differences; that is, it measures the bio-
chemical expression of genes under a specific set of conditions
rather than the presence of specific genes. As variations in bio-
chemical composition among different taxa may be slight,
spectral reproducibility depends on stringent control of sampling
and measurement conditions. The composition of the growth
medium and phase of growth (stationary versus exponential) are
critical, as relative peak intensities may be affected much more
(because of changes in metabolite pools) than peak positions.32
FTIR analysis thus depends very much on fidelity in the repro-
duction of growth media, culture handling techniques and
culture conditions.31,33,34 An ‘IR grade’ standard blood-free syn-
thetic growth medium, namely Que-Bactw Universal Medium
No. 2 developed by Quelab Laboratories Inc., and strict obser-
vance of 18 h incubations at 378C to obtain early stationary-
phase cells on a consistent basis were employed in the present
study.
There is a theoretical possibility of variance due to carry-over
(from the medium used to reactivate the frozen strains) of sheep
blood from different sources. Three years of practice have indi-
cated that this does have any appreciable impact on spectral
FTIR spectroscopic identification of glycopeptide-intermediate S. aureus
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consistency (data not shown). It is also important to collect colo-
nies uncontaminated by agar. This is ensured using a large
plastic loop that gathers a large amount of bacterial growth
without scraping the agar surface. The exact manner in which
different individuals collect the growth and produce the cell sus-
pension could introduce variance, but no spectral variations
were attributable to this factor.
For spectra acquired in the transmission mode, reproducibility
is affected by sample uniformity, in particular homogeneity, par-
ticle size and thickness or light path length.35 Drying a 25 mL
droplet of diluted bacterial suspension for 1 h at 488C yielded a
transparent and uniform film and avoided baseline variations as
well as scattering, diffraction and refraction of the infrared
beam. Variations in the sample thickness cause band intensity to
vary, although relative peak intensities may be maintained.
Comparison of the spectra between 1800 and 800 cm21 of the
four films prepared for each isolate (from a suspension of colo-
nies from four separate plates) yielded an average correlation
coefficient of r ¼ 0.97 (data not shown). Variations were further
minimized by normalization to unit peak height and transform-
ation to the first derivative, which highlights spectral shapes and
contours and removes the effects of baseline shift, assuming that
the spectra possess a sufficient signal-to-noise ratio. Finally, the
use of a highly hygroscopic FTIR spectrometer equipped with a
ZnSe beamsplitter improves reproducibility for long-term intra-
and inter-laboratory comparisons.
Spectral differences between MRSA and GISA/hGISA
Infrared spectra of microorganisms have extensive overlap
because of bio-molecules common to all cells, and the subtle
differences among strains may be difficult to detect. The differ-
entiation of GISA/hGISA and MRSA on the basis of their FTIR
spectra may be categorized as a pattern recognition task. As in
any such task, feature extraction using the SVD algorithm may
assist in the selection of spectral regions for identification pur-
poses. A random selection among the 240 spectra obtained for
the 35 GISA/hGISA and 25 NML epidemic MRSA isolates
allowed us to identify two narrow regions with clear differences
using SVD: (i) 1480–1460 cm21 (Figure 1), assignable to defor-
mation vibrations of C-H bonds in methylene (CH2) groups of
lipids and proteins; and (ii) 1352–1315 cm21 (Figure 2), attribu-
table to symmetric stretching vibrations of carboxyl groups of
amino acid side chains or free fatty acids.
Discrimination between MRSA and GISA/hGISA based
on the 1480–1460 cm21 region
The first three principal components (PC1, PC2 and PC3)
accounted for over 99.94% of the total variance, with PC1 and
PC2 alone accounting for 97.92% and 1.84%, respectively. The
PCA scores plot (PC1 versus PC2) gave two distinct clusters,
corresponding to MRSA and GISA/hGISA (Figure 3). Two
GISA/hGISA isolates, NRS4 and NRS68, were misclassified as
MRSA, yielding an overall correct classification of 96.67%.
Visual inspection of an SOM of size [14  6] generated by non-
linear projection of the PC1 and PC2 scores and trained using a
rough training phase of 4 iterations and a fine-tuning phase of
14 epochs also indicated two distinct clusters corresponding to
MRSA and GISA/hGISA (Figure 4). The learning rate decreased
linearly to zero during the fine-tuning phase with a final quanti-
zation error of 0.162 and a final topographic error of 0.048,
yielding an overall correct classification of 98.34% with a single
misclassified GISA/hGISA isolate, NRS68. This misclassified
isolate cannot be visualized, as only the BMUs are shown. None
of the four NRS68 replicates were classified as a BMU and
therefore could be visualized only when plotting all data neigh-
bours and BMUs at the same time, which would make the map
difficult to visualize because of the large number of data. The
supervised cluster analysis using the KNN algorithm with 120
spectra as the training set and the remaining 120 spectra as the
test set gave 100% correct classification with K ¼ 1 and K ¼ 2.
Discrimination between MRSA and GISA/hGISA based
on the 1352–1315 cm21 region
Using the region 1352–1315 cm21, clustering of epidemic
MRSA and GISA/hGISA was 100% correct by PCA, SOM and
Figure 1. FTIR spectra of GISA/hGISA (solid lines) and MRSA (dotted
lines) in the region 1480–1450 cm21. A colour version of this figure is
available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/).
Figure 2. FTIR spectra of GISA/hGISA (solid lines) and MRSA (dotted
lines) in the region 1380–1280 cm21. A colour version of this figure is
available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/).
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KNN. Two distinct clusters of GISA/hGISA and epidemic
MRSA were clearly visible on the PCA plot and on an SOM of
size [16  5] generated by non-linear projection of the PC1 and
PC2 scores for this region using 4 iterations for rough training
and 13 epochs for the fine-tuning phase (data not shown). The
final quantization error was 0.128 with a final topological error
of 0.008. Using half of the data set (n ¼ 120) as the training set
and the other half as the prediction set, the KNN algorithm was
most effective for K ¼ 1 and K ¼ 2.
Discrimination between epidemic MRSA/sporadic MRSA
and GISA/hGISA
Twenty-two sporadic MRSA isolates were added to investigate
the ability of FTIR to distinguish GISA/hGISA from both spora-
dic and epidemic MRSA. The expanded data set contained four
replicate spectra for each isolate for a total of 328 spectra. The
region 1352–1315 cm21, although suitable for discriminating
between epidemic MRSA and GISA/hGISA, proved unsuitable
for discriminating between sporadic MRSA and GISA/hGISA,
yielding an overall correct classification of only 84.15% by
PCA, with 13 sporadic MRSA misclassified (data not shown).
Some improvement was obtained using PCA with the region
1480–1460 cm21. The first three PCs contained over 99.9% of
the overall total variance, with totals of 98.18%, 99.75% and
99.93% for PC1, PC2 and PC3, respectively, the scores plot of
PC1 versus PC2 revealing two distinct clusters corresponding to
GISA/hGISA and MRSA (data not shown). However, three
sporadic MRSA isolates (715, 864 and 693) were misclassified
as GISA/hGISA strains and a single sporadic MRSA (105) fell
between the GISA/hGISA and MRSA cluster. The same two
GISA/hGISA strains already mentioned (NRS4 and NRS68) fell
within the MRSA cluster, yielding 92.69% overall correct classi-
fication. The SOM algorithm sorted the scores of PCs 1 and 2
into clear clusters of GISA/hGISA and MRSA (data not shown)
with sporadic MRSA isolates 182, 715, 864 and 693 as well as
GISA/hGISA isolates NRS4 and NRS68 misclassified, yielding
92.69% overall correct classification. The map of size [13  7]
was trained using a short rough training phase of three iterations
that corresponded to the first stage in which the initial order is
formed. The initial weight vector, a large neighbourhood radius
and a large learning rate were then applied and the remaining
iteration stages constituted a fine-tuning phase of 11 epochs in
which both learning rate and neighbourhood radius began at
small values and were gradually reduced at each iteration. The
learning rate decreased linearly to zero during the fine-tuning
phase with a final quantization error of 0.173 and a final topo-
graphic error of 0.009. Supervised classification performed with
the KNN algorithm using half of the data set (n ¼ 170) as the
training set and the other half as the prediction set gave a
slightly higher correct classification of 93.9% using K ¼ 7. The
same three sporadic MRSA (715, 864 and 693) and the same
two GISA/hGISA (NRS4 and NRS68) misclassified by the PCA
scores plot were also misclassified by KNN. The single sporadic
MRSA (105) that fell between the GISA/hGISA and MRSA
clusters was correctly classified on the basis of the class of the
majority of its nearest neighbouring known samples.
Validation of the FTIR method
The robustness of the differentiation using the 1480–1460 cm21
region was assessed by challenging it with another collection of
epidemic MRSA isolates. Sixty of these were collected by
NML from various Canadian sources, whereas the other 25 were
provided by a single hospital (Montreal Royal Victoria).
Classification of a set containing these plus the original 35
GISA/hGISA strains was 98.34% correct by PCA with the same
GISA/hGISA isolates as mentioned above misclassified (NRS4
and NRS68) and 99.37% correct by SOM and KNN for K ¼ 3
with a single strain of GISA (NRS 68) misclassified. When
these 85 epidemic MRSA were combined with the initial
Figure 3. Scores plot for the first two principal components obtained from
FTIR spectra of GISA/hGISA (filled triangles) and MRSA (open circles) in
the region 1480–1460 cm21. A colour version of this figure is available as
Supplementary data at JAC Online (http://jac.oxfordjournals.org/).
Figure 4. SOM obtained using FTIR spectral profiles of GISA/hGISA (G)
and MRSA (M) in the region 1480–1460 cm21. A colour version of this
figure is available as Supplementary data at JAC Online (http://jac.
oxfordjournals.org/).
FTIR spectroscopic identification of glycopeptide-intermediate S. aureus
99
expanded set of 82 isolates (i.e. including the sporadic MRSA),
the same four sporadic MRSA (715, 693, 864 and 105) and two
GISA/hGISA (NRS4 and NRS68) strains remained misclassified
by PCA but the larger set increased the percent correct classifi-
cation from 92.69% to 96.41%. For SOM, sporadic MRSA iso-
lates 715, 693, 864 and 182 were again misclassified as well as
GISA/hGISA isolates NRS4 and NRS68, thus increasing the
correct classification from 92.69% to 96.41% as for PCA.
Correct classification by the KNN analysis also increased, from
93.90% to 97.01% for K ¼ 7, with the same three sporadic
MRSA (715, 693 and 864) and the same GISA/hGISA (NRS4
and NRS68) misclassified.
Other work has shown that Enterococcus casseliflavus and
Enterococcus gallinarum with intrinsic low-level vancomycin
resistance were correctly identified by FTIR spectroscopy18
using a combination of equally weighted broad spectral ranges
(1500–1200, 1200–900, 900–700 cm21) of first-derivative
spectra. However, these species were not distinguished from
vancomycin-susceptible strains of identical species. Our present
study is the first demonstration of reliable identification of
glycopeptide-intermediate S. aureus by FTIR spectroscopy.
The decrease in the discrimination between epidemic MRSA
and GISA/hGISA from 100% to 84.15% with 13 sporadic
MRSA misclassified indicates poor specificity in the 1352–
1315 cm21 region. This may indicate heterogeneity of this phe-
notype, resulting from the acquisition of SCCmec by strains of
different genetic background. In comparison, discrimination
using the spectral region of 1480–1460 cm21, containing pri-
marily absorption bands that may be assigned to CH2 asym-
metric bending vibrations of lipids and proteins,36,37 was not
affected by the inclusion of the 22 sporadic MRSA isolates. On
the basis of the interpretations for MIC breakpoints and rec-
ommendations of the CDC38 and CLSI,39 the misclassified
GISA/hGISA NRS4 has shown intermediate resistance to vanco-
mycin and teicoplanin by BHIA-MMET and a susceptible-
resistant pattern by all other screening methods (BMD,
MHA-CMET, BHIA-6V and DD), except for intermediate teico-
planin resistance using MHA-CMET. The other misclassified
GISA/hGISA (NRS68) has shown intermediate resistance to
vancomycin and susceptibility to teicoplanin using BHIA-
MMET. All the other screening methods used (BMD, MHA-
CMET, BHIA-6V and DD) have indicated no resistance to either
glycopeptide. The four sporadic MRSA strains (715, 864, 693
and 105) apparently misclassified by FTIR as glycopeptide inter-
mediate using PCA, as well as the sporadic MRSA 182 misclas-
sified by SOM, have never in fact been tested for glycopeptide
susceptibility.
An explanation for the repeated misclassification of GISA/
hGISA isolates NRS4 and NRS68 by PCA and KNN could not
be advanced on the basis of their vancomycin and teicoplanin
susceptibility patterns. However, it should be noted that the
glycopeptide-intermediate resistance phenotype may be unstable
and affected by subculture methodology, repeated subculture or
by different growth media used prior to susceptibility testing.
Uniform decreases in vancomycin and teicoplanin MICs
occurred after 15 days of serial passage on non-selective
medium,40 – 42 a situation that provides an opportunity for rever-
sion to occur. Reversion of the glycopeptide-intermediate resist-
ance phenotype can occur in all types of GISA/hGISA
isolates,40,42,43 although it appears to depend on the genetic
background of the bacterial strain to some extent.40 This
reversion may account for some of the difficulties in identifying
them in the clinical laboratory and may explain the misidentifi-
cation of isolates NRS4 and NRS68. All isolates in the present
study were activated in the blood agar and cultured on
Que-Bactw Universal Medium No. 2, both without glycopep-
tides, prior to FTIR analysis.
The identification of GISA/hGISA isolates NRS4 (HIP5836)
and NRS68 should be confirmed by quantitative susceptibility
and confirmatory testing using PAPs, whereas the sporadic
MRSA strains 715, 864, 693, 105 and 182 should be tested for
glycopeptide resistance by conventional screening methods to
determine whether or not our FTIR method did in fact misclas-
sify them.
Conclusions
On the basis of the results of this study, FTIR spectroscopy
combined with the use of growth medium Que-Bactw Universal
Medium No. 2 and chemometric analysis of spectral data appear
to offer a promising alternative to conventional susceptibility
testing methods for routine identification of GISA/hGISA and
accordingly warrant further validation studies to confirm the
suitability of this technique for rapid screening of these strains.
In addition, further investigation of the spectral differences
between MRSA and GISA/hGISA isolates observed in this study
may aid in the elucidation of the mechanisms of glycopeptide
resistance in MRSA.
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